Nov 12 (Reuters) - Sun Biopharma Inc :
* SUN BIOPHARMA, INC. PROVIDES BUSINESS UPDATE AND REPORTS Q3 2020 FINANCIAL RESULTS
* Q3 LOSS PER SHARE $0.21
* UPCOMING MILESTONES INCLUDE COMPLETING SBP-101'S ENROLLMENT IN CURRENT PHASE 1B TRIAL IN Q4
* SUN BIOPHARMA - BELIEVE SBP-101 HAS POTENTIAL TO EXPAND INTO OTHER CANCERS WITH KNOWN ELEVATED LEVELS OF POLYAMINE METABOLISM
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.